The attitude of physicians regarding the promotion strategies of the pharmaceutical industry;Actitud de los médicos frente a las prácticas de promoción de la industria farmacéutica

Medicina

Volumn 65, Issue 3, 2005, Pages 247-251

  Castresana, Leonardo ^a,b   Mejía, Raúl ^a   Aznar, Mireya ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b NONE   (Argentina)

Author keywords

Conflict of interest; Gift giving; Medical samples; Pharmaceutical industry

Indexed keywords

ADULT; ARGENTINA; ARTICLE; DRUG INDUSTRY; DRUG MARKETING; FEMALE; HEALTH SURVEY; HOSPITAL; HUMAN; MALE; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MEDICAL STAFF; PHYSICIAN ATTITUDE; PRESCRIPTION; PUBLIC RELATIONS; ADVERTIZING; AGED; CONFLICT OF INTEREST; CROSS-SECTIONAL STUDY; ETHICS; MEDICAL ETHICS; MIDDLE AGED;

ADULT; ADVERTISING; AGED; ARGENTINA; CONFLICT OF INTEREST; CROSS-SECTIONAL STUDIES; DRUG INDUSTRY; ETHICS, MEDICAL; FEMALE; HUMANS; INTERPROFESSIONAL RELATIONS; MALE; MIDDLE AGED;

EID: 21844472998     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wazana A. Physicians and the pharmaceutical industry. Is a gift ever a gift? JAMA 2000; 283: 373-80.
2. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982; 73: 4-8.
3. Coyle S. Physician-Industry relations. part 1. Ann Intern Med 2002;136: 396-402.
4. Mejía R, Avalos A. Material informativo entregado por los agentes de propaganda médica. Medicina (Buenos Aires) 2001; 61: 315-18.
5. Chew L, O'Young T, Hazlet T, Bradley K, Maynard C, Lessler D. A physician survey of the effect of drug sample availability on physicians behavior. J Gen Intern Med 2000;15: 478-83.
6. Lexchin J. What information do physicians receive from pharmaceutical representatives?. Can Fam Physician 1997; 43: 941-5.
7. Shaugnessy A, Slawson D, Bennett J. Separating the wheat from the chaff: Identifying fallacies in pharmaceutical promotion. J Gen Intern Med 1994; 9: 563-8.
8. Thomson AN, Craig BJ, Barham PM. Attitudes of general practitioners in New Zealand to pharmaceutical representatives. Br J Gen Pract 1994; 44: 220-3.
9. Stross J. Information sources and clinical decisions. J Gen Intern Med 1987; 2: 155-9.
10. Caudill TS, Johnson MS, Rich EC, Mc Kinney W. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med 1996; 5: 201-6.
11. Grifith D. Reasons for not seeing drug representatives. Lightening workload, cutting costs and improving quality. BMJ 1999; 319: 69-70.
12. Donabedian A. The quality of care: How can it be assessed? JAMA. 1988; 260: 1743-8.
13. Blumenthal D, Ferris T. The quality of primary care.In: Up To date, Wellesley, MA: Rose BD (Ed), 2003.
14. Chren M, Landefeld S. Physicians behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994; 271: 684-9.
15. Watkins C. Characteristics of general practitioners who frequently see drug representatives: national cross sectional study. BMJ 2003; 326: 1178-9.
16. Ethics manual. Fourth edition. American College of Physicians. Ann Intern Med 1998; 128: 576-94
17. Gibbons R, Landry F, Blouch D, et al. A comparison of physicians and patients attitudes toward pharmaceutical industry gifts. J Gen Intern Med 1998; 13: 151-4.
18. Streiner D. Scaling responses in health measurement scales. New York: Oxford University Press, 1995. pp 29-53.
19. Kamran A, Richard S. No more free lunches. Patients will benefit from doctor's and drug companies disentangling. BMJ 2003; 326: 1155-6.
20. American Medical Association. Ethical guidelines for gifts to physicians from industry. 2001. www.ama-assn.org (consultada 11/10/2003)
21. Organización Mundial de la Salud. Criterios para la promoción de drogas. www.who.int (consultada 11/10/2003).
22. Coyle S. Physician-Industry relations. part 2. Ann Intern Med 2002; 136: 403-6.
23. Moynihan R. Who pays for de pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. BMJ 2003; 326: 1189-92.
24. Poirier T, Giannetti V, Giudici R. Pharmacists and Physicians attitudes toward pharmaceutical marketing practices. Am J Hosp Pharm 1994; 51: 378-81.
25. Landefeld S, Chren M. Drug companies and information about drugs: Recommendations for Doctors. Characteristics of materials distributed by drug companies: Four points of view. JGIM 1996; 11: 642-3.
26. Turone F. Italian police investigate Glaxo Smith Kline for bribery. BMJ 2003; 326: 413
27. Wager E. How to dance with porcupines: rules and guide-lines on doctor's relations with drug companies. BMJ 2003; 326: 1196-8.
28. Ethics Commitee for the American College of Physicians. Physicians and the pharmaceutical industry. Ann Intern Med. 1990; 112: 624-6.
29. Moynihan R. Who pays for de pizza? Redefining the relationships between doctors and drug companies.2: Disentanglement. BMJ 2003; 326: 1193-6.
30. American Medical Student Association. Pharmfree campaign. AMSA 2002. www.amsa.org (consultada 11/10/2003).
31. ABIM Foundation, ACP-ASIM Foundation, European federation of Internal Medicine. Medical professionalism in the new millennium: A physician charter. Ann Intern Med 2002; 136: 243-6.